Menu
Search
|

Menu

Close
X

OHR Pharmaceutical Inc OHRP.OQ (NASDAQ Stock Exchange Capital Market)

0.20 USD
-0.00 (-0.50%)
As of Jul 20
chart
Previous Close 0.20
Open 0.20
Volume 6,262
3m Avg Volume 72,219
Today’s High 0.21
Today’s Low 0.20
52 Week High 2.17
52 Week Low 0.18
Shares Outstanding (mil) 56.21
Market Capitalization (mil) 39.03
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.113
FY17
-0.587
FY16
-0.822
FY15
-0.544
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
1.40
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.57
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-88.21
14.61
Return on Equity (TTM)
vs sector
-88.44
16.34

EXECUTIVE LEADERSHIP

Michael Ferguson
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Jason Slakter
President, Chief Executive Officer, Director, Since 2015
Salary: $200,000.00
Bonus: --
Sam Backenroth
Chief Financial Officer, Vice President - Business Development, Since 2012
Salary: $200,000.00
Bonus: --
June Almenoff
Independent Director, Since 2013
Salary: --
Bonus: --
Orin Hirschman
Independent Director, Since 2009
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

800 3rd Ave Fl 11
NEW YORK   NY   10022-7651

Phone: +1212.6828452

Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company's animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin. It also owns various other compounds in earlier stages of development, including the PTP1b inhibitor Trodusquemine and related analogs.

SPONSORED STORIES